This article discusses how Alzheimer’s treatment is entering a new era with the development of disease-modifying therapies (DMTs). Unlike traditional medications that only temporarily improve symptoms such as memory or attention, these newer therapies aim to slow the biological progression of the disease itself by targeting amyloid proteins in the brain.

The article highlights monoclonal antibody treatments such as lecanemab and donanemab, which work by helping the immune system remove amyloid plaques associated with Alzheimer’s disease. Clinical trials have shown that these treatments can modestly slow cognitive decline in people with early-stage Alzheimer’s disease or mild cognitive impairment. Researchers view this as a major shift in dementia care because it demonstrates, for the first time, that altering the underlying pathology of Alzheimer’s may change disease progression.

A major theme of the article is that the benefits of these therapies are greatest when Alzheimer’s disease is detected early. As a result, there is increasing emphasis on biomarkers such as amyloid PET scans, cerebrospinal fluid analysis, and newer blood biomarkers like p-tau217 to identify patients before significant brain damage occurs.

The article also notes important limitations and challenges. Current disease-modifying therapies do not cure Alzheimer’s disease, and their clinical benefits remain moderate. They also require careful monitoring because of potential side effects, including brain swelling or bleeding. In addition, healthcare systems may need major adaptations to support widespread biomarker testing, imaging, infusion clinics, and long-term monitoring.

Overall, the article argues that Alzheimer’s care is shifting from symptom management toward earlier diagnosis, personalized medicine, and biologically targeted treatment strategies.